Ansuvimab

(Ebanga®)

Ebanga®

Drug updated on 11/14/2023

Dosage FormInjection (intravenous: 400 mg lyophilized powder )
Drug ClassZaire ebolavirus glycoprotein directed human monoclonal antibodies
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • For the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection.

Product Monograph / Prescribing Information

Document TitleYearSource
Ebanga (ansuvimab-zykl) Prescribing Information.2021Ridgeback Biotherapeutics, LP, Miami, FL

Systematic Reviews / Meta-Analyses